Program
IN-B00009
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity, led by HK inno.N.
Furthest: phase 3, since Sep 8, 20252 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HK inno.N | 22 open or running | phase 3since Sep 8, 2025 | Sep 8, 2025 | Dec 31, 2026phase 3 · NCT07192263 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2025First study: phase 3 study in ObesityFirst studyNCT07192263 · 300 planned
- Dec 15, 2025Phase 3 study in Diabetes MellitusNCT07308184 · 110 planned
Ahead
- Dec 31, 2026Primary completion: phase 3 study in ObesityNCT07192263
- Aug 2027Primary completion: phase 3 study in Diabetes MellitusNCT07308184
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07308184Diabetes Mellitus | 3 | Not yet recruiting | Aug 2027 | 110 |
| NCT07192263Obesity | 3 | Not yet recruiting | Dec 31, 2026 | 300 |
How it is read
Names in the registry
- “IN-B00009”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.